EML4 and non-small cell lung carcinoma: This was first developed in 2015 when preclinical work showed that vaccination of transgenic mice with EML4-ALK variant 1 induced a strong immune response and prophylactically and therapeutically impaired the growth of ALK+ NSCLC tumors[140].